Deferred Action for Childhood Arrivals
- Details
- Written by DHS
- Category: News
Washington, DC - Acting Department of Homeland Security Press Secretary Tyler Q. Houlton Statement on Deferred Action for Childhood Arrivals:
Free Software Can Help Spot New Forms of Fentanyl and Other Illegal Drugs
- Details
- Written by Rich Press
- Category: News
Washington, DC - Fentanyl, the synthetic drug that is driving a nationwide overdose epidemic, is not only a killer. It’s also a shape shifter. Illicit chemists are constantly cooking up new forms of fentanyl, each with a slightly different chemical structure, stymieing law enforcement and putting users at greater risk.
J.M. Smucker Company's Decision to Drop Proposed Acquisition of Conagra Brands Inc
- Details
- Written by IVN
- Category: News
Washington, DC - Following yesterday’s announcement by J.M Smucker, Ian Conner, Deputy Director of the Bureau of Competition, made this statement:
Facebook Upgrades Link Structure to Include HSTS Preloading
- Details
- Written by Patrick Nohe - HashedOut
- Category: News
Jacksonville, Florida - On Monday morning, Facebook announced that it had upgraded its link structure to include HSTS preloading. This is great news for a more secure internet as it will help to continue the proliferation of encryption across the internet.
FDA authorizes direct-to-consumer test that reports three mutations in the BRCA breast cancer genes
- Details
- Written by IVN
- Category: News
Washington, DC - The U.S. Food and Drug Administration today authorized the Personal Genome Service Genetic Health Risk (GHR) Report for BRCA1/BRCA2 (Selected Variants). It is the first direct-to-consumer (DTC) test to report on three specific BRCA1/BRCA2 breast cancer gene mutations that are most common in people of Ashkenazi (Eastern European) Jewish descent. These three mutations, however, are not the most common BRCA1/BRCA2 mutations in the general population.
FDA approves new HIV treatment for patients who have limited treatment options
- Details
- Written by IVN
- Category: News
Washington, DC - Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.
Page 985 of 3785
- You are here:
-
Home
- News